Age-related trends (1986-1993) in the use of thrombolytic agents in patients with acute myocardial infarction: The Worcester Heart Attack Study

Archives of Internal Medicine

Volumn 157, Issue 7, 1997, Pages 741-746

  Chandra, Harish ^a   Yarzebski, Jorge ^a   Goldberg, Robert J ^a   Savageau, Judith ^a   Singleton, Colleen ^a   Gurwitz, Jerry H ^a   Gore, Joel M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FIBRINOLYTIC THERAPY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030894615     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.7.741     Document Type: Article

References (36)

1. Pashas CL, Newhouse JP, McNeil BJ. Temporal changes in the care and outcomes of elderly patients with acute myocardial infarction, 1987 through 1990. JAMA. 1993;270:1832-1836.
2. Gurwitz JH, Goldberg RJ, Chen Z, Gore J, Alpert JS. Recent trends in hospital mortality of acute myocardial infarction: have improvements been realized for all age groups? the Worcester Heart Attack Study (1975-1990). Arch Intern Med. 1994;154:2202-2208.
3. Goldberg RJ, Gore JM, Gurwitz JH, et al. The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J. 1989;117:543-549.
4. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. Am J Med. 1992;93:605-610.
5. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the cooperative cardiovascular projects. JAMA. 1995;273:1509-1514.
6. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national consensus guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996;156:799-805.
7. GISSI (Gruppo Italiano Per Lo Studio Delia Streptochinasi Nell'infarto Miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988; 2:349-360.
9. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545-549.
10. Wilcox RG, Olsson CG, Skene AM, von der Lipe G, Jenset G, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolyis (ASSET). Lancet. 1988;2:525-530.
11. Wilcox RG, von der Lippe G, Olssoh CG, Jensen G, Skene AM, Hampton JR. Effects of alteplase in acute myocardial infarction: 6-months results from the ASSET Study. Lancet 1990;335:1175-1178.
12. Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly? JAMA. 1991;265:1720-1723.
13. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-322.
14. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 1992;327:7-13.
15. Weaver WD, Litenin PE, Martin JS, et al. The MITI Project Group: effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol. 1991;18:675-762.
16. Yarzebski J, Col N, Pagley P, Savageau J, Gore JM, Goldbert RJ. Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: a community-wide perspective. Am Heart J. 1996;131:44-49.
17. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med. 1996;124:283-291.
18. Goldberg RJ, Gurwitz J, Yarzebski J, et al. Patient delay and receipt of thrombolytic therapy among patients with acute myocardial infarction from a community-wide perspective. Am J Cardiol. 1992;70:421-425.
19. Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med. 1990;113:949-960.
20. GISSI-2. A randomized trial of alteplase versus streptokinase and heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
21. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Recent changes in the attack rates and survival rates of acute myocardial infarction (1975-1981): the Worcester Heart Attack Study. JAMA. 1986;255:2774-2779.
22. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Incidence and case fatality rates of acute myocardial infarction (1975-1984): the Worcester Heart Attack Study. Am Heart J. 1988;115:761-767.
23. Goldberg RJ, Gorak EJ, Yarzebski J, et al. A community-wide perspective of gender differences and temporal trends in the incidence and survival rates following acute myocardial infarction and out-of-hospital deaths due to coronary heart disease. Circulation. 1993;87:1947-1953.
24. Pagley PR, Yarzebski J, Goldberg RJ, et al. Gender differences in the treatment of patients with acute myocardial infarction: a multi-hospital, community-based perspective. Arch Intern Med. 1993;153:625-629.
25. Chiriboga DE, Yarzebski J, Goldberg RJ, et al. A community-wide perspective of gender differences and temporal trends in the use of diagnostic and revascularization procedures for acute myocardial infarction. Am J Cardiol. 1993; 71:268-273.
26. Pashos CL, Normand ST, Garfinkle JB, Newhouse JP, Epstein AM, McNeil BJ. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol. 1994;23:1023-1030.
27. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med. 1991;115:173-177.
28. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90:2103-2114.
29. Goldberg RJ. A community-wide perspective of secular trends in the therapeutic management of patients with acute myocardial infarction: the Worcester Heart Attack Study. Cardiology. 1989;76:105-111.
30. Goldberg RJ. Temporal trends and declining mortality rates from coronary heart disease in the United States. In: Ockene IS, Ockene JK, eds. Prevention of Coronary Heart Disease. Boston, Mass: Little Brown & Co Inc; 1992:41-68.
31. Col NF, McLaughlin TJ, Soumerai SB, et al. The impact of clinical trials on the use of medications for acute myocardial infarction: results of a community-based study. Arch Intern Med. 1996;156:54-60.
32. Krumholz HM, Friesinger GC, Cook EF, Lee TH, Rouan GW, Goldman L. Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction. J Am Geriatr Soc. 1994; 42:127-131.
33. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995; 10:321-330.
34. Third International Study of Infarct Survival Collabortive Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs antistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
35. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329:673-682.
36. Maggioni AP, Franzosi MG, Santoro E, et al. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med. 1992;327:1-6.